TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1363727

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 160

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 160
Study: 6499702

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study: 30698279

Group type: EXPERIMENTAL
Intervention: Vitamin D3 adjusted to maintain serum 25(OH)D above 30 ng/mL
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 29615123

Group type: EXPERIMENTAL
Intervention: EU EXPEDITION patients (n = 133)
Number of subjects: 734

Group type: COMPARATOR
Intervention: GERAS patients (n = 417)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Sensitivity analysis comparing EU/NA EXPEDITION patients with GERAS patients
Number of subjects: 734
Study: 28042304

Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy for poststroke urinary incontinence (10 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham therapies (10 sessions)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham therapies
Number of subjects: 40
Study: 25887891

Group type: EXPERIMENTAL
Intervention: Basic intervention (cognitive and self-regulation processes)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Plus intervention (cognitive, self-regulation processes, and environmental-level factors)
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Control group (generic nutrition information)
Number of subjects: 1349
Study: 22001552

Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release plus escitalopram
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release plus mirtazapine
Number of subjects: 665

Group type: COMPARATOR
Intervention: Participants with HD
Number of subjects: 665

Group type: COMPARATOR
Intervention: Participants without HD
Number of subjects: 665
Study: 20021517

Group type: EXPERIMENTAL
Intervention: CT overlay (group 1, n = 38)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CartoMerge (group 2, n = 30)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CT overlay (group 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CartoMerge (group 2)
Number of subjects: 68
Study: 18637586

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (40/320 mg, DP, group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (20/120 mg tablets, AL, group B)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Comparison between AL and DP
Number of subjects: 106
Study: 15930065

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive therapy (N=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Standard cognitive therapy (N=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait list control group (N=15)
Number of subjects: 45
Study: 12912780

Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling aimed at decreasing intake of saturated fat and cholesterol, provided since the children were 8 months old.
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control group (no dietary counseling).
Number of subjects: 435
Study: 10513802

Group type: EXPERIMENTAL
Intervention: Global statistical tests (GSTs)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Joint swelling and joint tenderness
Number of subjects: 3

Group type: COMPARATOR
Intervention: ACR criteria
Number of subjects: 3
Study: 8562399

Group type: EXPERIMENTAL
Intervention: Competitive ELISA assay for platelet HPA1a typing
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control samples stored as whole blood
Number of subjects: 475
Study: 1881502

Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine 800 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Maalox (liquid aluminium/magnesium hydroxide antacid)
Number of subjects: 10
Study: 754193

Group type: EXPERIMENTAL
Intervention: Exposure to artificial electromagnetic (ac) fields
Number of subjects: 14

Group type: COMPARATOR
Intervention: Shielding of the kidney area
Number of subjects: 14

Group type: COMPARATOR
Intervention: Shielding of the head
Number of subjects: 14
Study: 31932171

Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Routine clinical assessment as directed by NICE CG95 guideline
Number of subjects: 1400
Study: 30862658

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 24 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28098097

Group type: EXPERIMENTAL
Intervention: N. sativa oil (2.5 mL, once daily, per orally) along with conservative management for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management of diabetic nephropathy
Number of subjects: 0
Study: 26148204

Group type: EXPERIMENTAL
Intervention: Tenofovir arm (TDF/emtricitabine)
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Abacavir arm
Number of subjects: 1096
Study: 23874469

Group type: EXPERIMENTAL
Intervention: Activating music
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronome stimuli
Number of subjects: 0
Study: 21797111

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg orally daily for six months plus carboplatin (AUC 7) intravenously every four weeks for up to six doses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carboplatin (AUC 7) intravenously every four weeks for up to six doses
Number of subjects: 40
Study: 19254585

Group type: COMPARATOR
Intervention: fFN 0 ng/mL
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: fFN 1-49 ng/mL
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: fFN 50-199 ng/mL
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: fFN > 200 ng/mL
Number of subjects: 563
Study: 17532241

Group type: EXPERIMENTAL
Intervention: Patching regimens (decreased prescribed hours)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Patching for only 2 hours
Number of subjects: 560
Study: 16179209

Group type: EXPERIMENTAL
Intervention: Cortical imaging protocol using MR acquisition and analysis methods
Number of subjects: 10
Study: 12843168

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Metyrapone administration
Number of subjects: 58
Study: 10073739

Group type: EXPERIMENTAL
Intervention: Cysteamine hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phosphocysteamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cysteamine bitartrate
Number of subjects: 18

Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cysteamine hydrochloride vs Phosphocysteamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cysteamine hydrochloride vs Cysteamine bitartrate
Number of subjects: 18
Study: 8849352

Group type: EXPERIMENTAL
Intervention: Combination treatment (5mg MTX/week plus 50 mg AZA/day to 7.5 mg MTX/week plus 100 mg AZA/day)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 50-150 mg/day
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 5-15 mg/week
Number of subjects: 209

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Combination treatment and Azathioprine (AZA)
Number of subjects: 209
Study: 2309991

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) with propofol and alfentanil infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced Anaesthesia (BA) with thiopental and fentanyl
Number of subjects: 40
Study: 345678

Group type: EXPERIMENTAL
Intervention: Respiratory Feedback (RFB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 31910030

Group type: COMPARATOR
Intervention: Glucose minimal model (MM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: NEFA minimal model (MM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison of fatty acids
Number of subjects: 66
Study: 29707579

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 91
Study: 26821247

Group type: EXPERIMENTAL
Intervention: Psychoeducation and yoga intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 24473367

Group type: COMPARATOR
Intervention: Normal-dose CTPA (100-kVp tube energy and 100-mL CM)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Low-dose CTPA (80-kVp tube energy and 75-mL CM)
Number of subjects: 501
Study: 22104075

Group type: EXPERIMENTAL
Intervention: Esophageal guidewire-assisted NGT insertion with manual forward laryngeal displacement (group 1)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Head flexion and lateral neck pressure (group 2)
Number of subjects: 480
Study: 19946699

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 26 Hz for five 1-min bouts
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-WBV treatment (stretching of the plantar flexors at end range of dorsiflexion for five 1-min bouts)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 12
Study: 18721711

Group type: EXPERIMENTAL
Intervention: ketorolac 0.4%
Number of subjects: 56

Group type: COMPARATOR
Intervention: bromfenac 0.09%
Number of subjects: 56
Study: 15649853

Group type: COMPARATOR
Intervention: Rac‐formoterol 36 microg
Number of subjects: 46

Group type: COMPARATOR
Intervention: (R;R)‐formoterol 18 microg
Number of subjects: 46

Group type: COMPARATOR
Intervention: (S;S)‐formoterol 18 microg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rac‐formoterol and (R;R)‐formoterol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: (R;R)‐formoterol
Number of subjects: 46
Study: 12236642

Group type: EXPERIMENTAL
Intervention: SyntacSprint (SS) and Tetric Ceram (TC) without base material
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dyract as base material with Tetric Ceram (TC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitremer as base material with Tetric Ceram (TC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chelon-fil as base material with Tetric Ceram (TC)
Number of subjects: 48
Study: 12669742

Group type: EXPERIMENTAL
Intervention: Alendronate 60 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Etidronate 400 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8697058

Group type: EXPERIMENTAL
Intervention: Sibutramine 5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine doses varying from 1 to 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sibutramine (various doses)
Number of subjects: 0
Study: 2132640

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 75 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 443256

Group type: EXPERIMENTAL
Intervention: 40 mg/day of prednisolone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31361535

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2)
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Bevacizumab (15 mg/kg)
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Combination of pemetrexed and bevacizumab
Number of subjects: 1516
Study: 27260003

Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 24-IPC
Number of subjects: 12

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPC and 24-IPC
Number of subjects: 12
Study: 25729933

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional group (moderate enteral nutritional support)
Number of subjects: 20
Study: 23940710

Group type: EXPERIMENTAL
Intervention: High proanthocyanidin intake (highest tertile)
Number of subjects: 948
Study: 21873661

Group type: EXPERIMENTAL
Intervention: Untreated POAG patients attending follow-up study (n = 47)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Peak IOP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 24-hour IOP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IOP fluctuation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison of glaucomatous eye vs. nonglaucomatous eye
Number of subjects: 66
Study: 19808128

Group type: EXPERIMENTAL
Intervention: Microplasmin 0.1 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 1.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 2 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 1 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 2 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 3 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 4 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16700280

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium Chloride (Placebo)
Number of subjects: 60
Study: 12911451

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (n = 36)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Abdominal hysterectomy (n = 38)
Number of subjects: 74
Study: 11093025

Group type: EXPERIMENTAL
Intervention: Ozone treatment for 10 seconds (0.069 ml of ozone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone treatment for 20 seconds (0.138 ml of ozone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone treatment for 10 seconds on S. mutans
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone treatment for 10 seconds on S. sobrinus
Number of subjects: 40
Study: 9194719

Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 400 mg 5 times a day for 3 weeks
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 1493321

Group type: EXPERIMENTAL
Intervention: Preservation of posterior mitral leaflet (PML) during mitral prosthesis implantation (MPI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Mitral prosthesis implantation (MPI) without preservation of PML
Number of subjects: 95
Study: 3923081

Group type: EXPERIMENTAL
Intervention: Tube feeding during radiation therapy
Number of subjects: 26
Study: 31566666

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 354
Study: 29848044

Group type: EXPERIMENTAL
Intervention: Workshops linking young women with existing government structural support programmes
Number of subjects: 3516

Group type: COMPARATOR
Intervention: Excluding Ipelegeng (a part-time minimum wage rotating employment scheme)
Number of subjects: 3516

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of all programmes
Number of subjects: 3516
Study: 25355728

Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Rituximab (both doses)
Number of subjects: 185
Study: 25227656

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 79
Study: 22004690

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 20196635

Group type: EXPERIMENTAL
Intervention: Flare-up group
Number of subjects: 221

Group type: COMPARATOR
Intervention: Antagonist group
Number of subjects: 221
Study: 18586174

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 15937757

Group type: EXPERIMENTAL
Intervention: PAmAb (0.3, 1.0, and 3.0 mg/kg intramuscular; 1.0, 3.0, 10, 20, and 40 mg/kg intravenous)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PAmAb (intramuscular and intravenous)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PAmAb (biological activity)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 105
Study: 12209671

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus bolus 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study: 10970079

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 60
Study: 8641910

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony stimulating factor (G-CSF) at a dose of 300 micrograms subcutaneously, administered on Friday, Saturday, and Sunday during the radiotherapy period.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Large-field radiotherapy without G-CSF (Control group).
Number of subjects: 15
Study: 1503284

Group type: COMPARATOR
Intervention: Methohexitone 9 mg.kg‐1.h‐1 for one hour (group M)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methohexitone 9 mg.kg‐1.h‐1 with fentanyl 7 micrograms.kg‐1.h‐1 for one hour (group MF)
Number of subjects: 14
Study: 6742535

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg X kg‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.02 mg X kg‐1)
Number of subjects: 10
Study: 31034304

Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (75 min/week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic training (MICT) (150 min/week)
Number of subjects: 18
Study: 28698692

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lidocaine and Dexmedetomidine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lidocaine-Dexmedetomidine
Number of subjects: 3
Study: 25327485

Group type: EXPERIMENTAL
Intervention: Acarbose 150 mg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no acarbose)
Number of subjects: 95
Study: 24502072

Group type: EXPERIMENTAL
Intervention: Clonidine 100 micrograms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21986123

Group type: EXPERIMENTAL
Intervention: Moist laparotomy pads (PAD group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Deep pericardial traction sutures (DPS group)
Number of subjects: 51
Study: 18372134

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 444
Study: 17072954

Group type: EXPERIMENTAL
Intervention: 10% sucrose syrup + levodopa for 3 days (Group 1)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo for levodopa + 10% sucrose syrup for 3 days (Group 2)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 10% sucrose syrup + levodopa for 7 days (Group 3)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo for levodopa + 10% sucrose syrup for 7 days (Group 4)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo for both sugar and levodopa for 7 days (Group 5)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo for both sugar and levodopa for 14 days (Group 6)
Number of subjects: 139
Study: 12924758

Group type: EXPERIMENTAL
Intervention: Condition with stable visual reference (walls and ceiling visible)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Condition without stable visual reference (curtains preventing view)
Number of subjects: 0
Study: 11097085

Group type: EXPERIMENTAL
Intervention: Memory remediation techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 9029458

Group type: EXPERIMENTAL
Intervention: Procera system for fabrication of crowns and fixed partial dentures
Number of subjects: 114
Study: 8501336

Group type: EXPERIMENTAL
Intervention: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with full strength bicarbonate buffer (4 g)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with half strength bicarbonate buffer (2 g)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Full strength buffer without vaccine
Number of subjects: 260

Group type: COMPARATOR
Intervention: Half strength buffer without vaccine
Number of subjects: 260
Study: 3471750

Group type: EXPERIMENTAL
Intervention: Imipenem 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Latamoxef 1 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Number of subjects: 10
Study: 2521060

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 64
Study: 29280043

Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 2 weeks
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 18 weeks plus weekly paclitaxel
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: TnT
Number of subjects: 173